{"entity":{"id":"paper-dhillon-mol-diagn-ther","kind":"paper","name":"Zevorcabtagene Autoleucel: First Approval","aka":[],"tldr":"Paper cited by one treatment page, indexed on Europe PMC as PubMed record 38888762 and published in Molecular diagnosis & therapy; the citing page links this DOI, which is how the record was matched.","summary":"Zevorcabtagene autoleucel () is a fully humanised B cell maturation antigen (BCMA)-targeting specific chimeric antigen receptor (CAR) T-cell therapy being developed by CARsgen for the treatment of multiple myeloma. Zevorcabtagene autoleucel is an autologous CAR T cell comprising a fully human BCMA-specific scFv (25C2), a CD8α hinge region and transmembrane domain, a 4-1BB costimulatory domain and a CD3-ζ T cell activation domain. Zevorcabtagene autoleucel recognizes and induces selective toxicity against BCMA-expressing tumour cells leading to their elimination. In February 2024, zevorcabtagene autoleucel received its first approval in China for the treatment of adults with relapsed or refractory multiple myeloma who have progressed after ≥ 3 prior lines of therapy (including ≥ 1 proteasome inhibitor and an immunomodulatory agent). Clinical studies of zevorcabtagene autoleucel are underway in Canada and the US. This article summarizes the milestones in the development of zevorcabtagene autoleucel leading to this first approval for relapsed or refractory multiple myeloma.\n\nIndexed on Europe PMC as PubMed record 38888762 (DOI 10.1007/s40291-024-00723-z). Matched by DOI alone: one treatment page cites this DOI among its external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Mol Diagn Ther 2024","url":"https://doi.org/10.1007/s40291-024-00723-z"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/38888762/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/38888762"}],"tags":["europepmc-ingest"],"related":["zevorcabtagene-autoleucel"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Molecular diagnosis & therapy","year":2024,"doi":"10.1007/s40291-024-00723-z","pmid":"38888762","authors":"Dhillon S","paperType":"review","findings":[],"whatItMeans":"One treatment page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.","caveats":["Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper."]},"route":"/key-papers/paper-dhillon-mol-diagn-ther/","neighbours":{"drug":[{"id":"zevorcabtagene-autoleucel","kind":"drug","name":"Zevorcabtagene autoleucel","route":"/drugs/zevorcabtagene-autoleucel/"}]}}